Charming Medical Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023
Revenue	5.42	6.22	6.02	3.53
Revenue Growth (YoY)	-14.36%	3.43%	70.37%	-
Cost of Revenue	0.22	0.2	0.17	0.05
Gross Profit	5.21	6.02	5.84	3.48
Selling, General & Admin	4.05	4.16	4.28	3.65
Operating Expenses	4.29	4.42	4.67	3.86
Operating Income	0.92	1.6	1.17	-0.38
Interest Expense	-0.02	-0.02	-0.03	-0.02
Interest & Investment Income	0.05	0.06	0.02	0.01
Other Non Operating Income (Expenses)	-0.13	-0.21	-0.16	-0.03
EBT Excluding Unusual Items	0.82	1.43	1	-0.42
Gain (Loss) on Sale of Investments	0.01	0	-	-
Pretax Income	0.84	1.44	1	-0.42
Income Tax Expense	0.18	0.24	0.18	-0.08
Earnings From Continuing Operations	0.66	1.2	0.82	-0.34
Minority Interest in Earnings	-	-	-0.04	0.03
Net Income	0.66	1.2	0.78	-0.31
Net Income to Common	0.66	1.2	0.78	-0.31
Net Income Growth	-24.65%	54.16%	-	-
Shares Outstanding (Basic)	15	15	15	15
Shares Outstanding (Diluted)	15	15	15	15
EPS (Basic)	0.04	0.08	0.05	-0.02
EPS (Diluted)	0.04	0.08	0.05	-0.02
EPS Growth	-24.65%	54.16%	-	-
Free Cash Flow	0.4	0.14	0.08	1.83
Free Cash Flow Per Share	0.03	0.01	0.01	0.12
Gross Margin	96.02%	96.76%	97.17%	98.66%
Operating Margin	16.99%	25.71%	19.49%	-10.73%
Profit Margin	12.12%	19.27%	12.93%	-8.64%
Free Cash Flow Margin	7.40%	2.22%	1.41%	51.76%
EBITDA	1.15	1.86	1.56	-0.17
EBITDA Margin	21.27%	29.95%	26.00%	-4.76%
D&A For EBITDA	0.23	0.26	0.39	0.21
EBIT	0.92	1.6	1.17	-0.38
EBIT Margin	16.99%	25.71%	19.49%	-10.73%
Effective Tax Rate	21.30%	16.45%	18.11%	-
Revenue as Reported	5.42	6.22	6.02	3.53
Advertising Expenses	-	1	0.86	0.66

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q